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Abstract
Bacterial and fungal infections are hallmarks of cystic fibrosis (CF) lung disease. In the era of long-term inhaled
antibiotics and increasing CF patient survival, new “emerging” pathogens are detected in CF airways, yet their
pathophysiological disease relevance remains largely controversial and incompletely defined. As a response to
chronic microbial triggers, innate immune cells, particularly neutrophils, are continuously recruited into CF airways
where they combat pathogens but also cause tissue injury through release of oxidants and proteases. The
coordinated interplay between host immune cell activation and pathogens is essential for the outcome of CF
lung disease. Here, we provide a concise overview and update on host-pathogen interactions in CF lung disease.
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CF lung disease
Lung disease determines the morbidity and mortality of
patients with cystic fibrosis (CF), a lethal monogenetic
disease caused by mutations in the cystic fibrosis trans-
membrane conductance regulator (CFTR) gene [21].
Hallmarks of CF lung disease are its chronic, non-
resolving and perpetuating nature. Importantly, a key
characteristic of CF lung disease is the early and main-
tained interplay of microbial infection and severe airway
inflammation [16]. The altered CF lung environment,
characterized by mucus obstruction, airway surface li-
quid dehydration, pH dysregulation (lower, acidic pH),
and high burden of extracellular proteases (mainly neu-
trophil elastase and matrix metalloproteases) favors mi-
crobial airway colonization and abnormal/inefficient
host immunity [16, 21]. While inflammation in general
is essential and indispensable to clear microbial infec-
tions and restore tissue integrity and homeostasis in
acute infective conditions such as bacterial pneumonia,
the pro-inflammatory response mechanisms activated in
CF lung disease seem to be acting in an excessive, non-
balanced, and therefore perpetuated manner [6]. The
resulting immune cell infiltration leads to irreversible
tissue remodeling with bronchiectasis and loss of lung
function. Overall, host-pathogen interactions in CF are
complex since they (1) depend on the individual CFTR
mutation class, (2) evolve mutually in a temporal and
spatial manner, and (3) are regulated by bacterial and
fungal phenotypes, such as biofilm formations [17, 28,
35]. Here, we aim to provide a concise overview on
host-pathogen interactions in CF lung disease in order
to shed light on new avenues for future research and
treatment approaches.
Microbial airway colonization in CF lung disease
CF airways are mainly colonized by specific bacteria and
fungi [28]. Among bacteria, Pseudomonas aeruginosa
and Staphylococcus aureus are the most abundant and
consequently most thoroughly studied pathogens. In
early infancy, CF airways are typically colonized with S.
aureus and Haemophilus influenzae. Later on in child-
hood, P. aeruginosa predominates and modulates disease
outcome substantially [3]. Upon chronic colonization, P.
aeruginosa can adapt this phenotype by conversion into
a mucoid form that is more resistant to antibiotics and
host defense. The majority of inhaled or systemic antibi-
otics used to treat CF patients is actually directed against
P. aeruginosa in order to eradicate or suppress this op-
portunistic Gram-negative bacterium [7]. The underlying
host-pathogen interaction mechanisms regulating the
CF-characteristic microbial “switch” from S. aureus and
H. influenzae to P. aeruginosa remain, however, contro-
versial and incompletely understood, but probably in-
volve pathogen-derived factors, such as pyocyanin and
host-derived immune factors as well as environmental
influences. In the era of commonly and early used
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inhaled antibiotics and prolonged patient survival, new
“emerging” pathogens are increasingly detected in CF
airway fluids, particularly fungi, such as Aspergillus fumi-
gatus [2, 26], Candida albicans [9, 10], and Scedospor-
ium species [22], and the bacteria Stenotrophomonas
maltophilia [13], Achromobacter xylosoxidans [12, 15],
methicillin-resistant S. aureus (MRSA) [14], Burkhol-
deria cepacia [11, 25], and atypical mycobacteria (nontu-
berculous mycobacteria, NTMs) [1, 23], which are often
hard to treat in the clinics due to antibiotic resistance
patterns [7, 8, 31, 33, 34]. Whereas the prevalence (or at
least the detection rate) of these microbial species in-
creases in most CF centers, their pathophysiological dis-
ease relevance for the outcome of CF lung disease
remains controversial and poorly defined. MRSA [14], B.
cepacia, and NTMs [23] are broadly accepted as harmful
CF pathogens, while for other rare species (such as S.
maltophilia [13, 30, 32]), this is less clear.
Host immunity
Faced with the presence of bacterial and fungal micro-
bial species, the host immune response reacts by recruit-
ing innate and adaptive immune cells into the infected
CF airway compartment. Among innate immune cells,
neutrophils are the most rapid and predominant cell
type transmigrating into CF airways, while in adaptive
immunity, T-helper cell type 2 (Th2) and Th17 cell re-
sponses are predominant [16], while regulatory T cell re-
sponses are impaired [18]. Remarkably, phagocytic
innate immune cells (neutrophils and macrophages)
preferentially accumulate within the airway compart-
ment, whereas, in contrast, lymphocytes are mainly
found in lung tissues, but are very low within the airway
lumen [24]. The underlying migratory and/or tissue
homeostatic mechanisms regulating this distinct im-
mune cell tissue compartment localization/distribution
remain to be defined, yet recent studies suggest that
neutrophils can suppress and thereby dampen T cell ac-
tivity at sites of inflammation [19]. When innate im-
mune cells are in physical contact with pathogens,
several factors decide which anti-microbial defense
mechanisms are employed; phagocytotic uptake is the
most rapid and principal effector function against
smaller bacteria and fungi, particularly after antibody-
and/or complement-mediated opsonisation [20]. If
pathogen size exceeds a critical threshold or pathogens
shield themselves through biofilms, neutrophils are un-
able to efficiently phagocytose pathogens and utilize
their extracellular host defense armamentarium, consist-
ing of neutrophil extracellular trap (NET) formation [4]
and the release of intracellularly stored anti-microbial ef-
fector proteins (such as defensins and proteases) [20]. In
CF airways in vivo, probably a combination of these host
defense mechanisms is operative, yet studies comparing
the relative contribution of these distinct neutrophil
functionalities to host defense outcome within the CF
airways are lacking (to the best of our knowledge). Be-
yond cellular mechanisms, studies involved a dysregu-
lated ceramide homeostasis/turnover in CF lung disease
by showing that ceramide accumulates in CF airways
and mediates inflammation, cell death, and infection
susceptibility [29].
Conclusion
Our understanding of host-pathogen interactions in CF
lung disease is continuously and substantially renewed
by current findings in microbiology (for instance by the
microbiome [27]) and immunology/cell biology (for in-
stance by the discovery of NET formation [5]). The chal-
lenge for the future remains to combine insights from
these two often disconnected scientific fields and to
translate them efficiently into the complex pathogenesis
of CF lung disease. A more precise dissection/stratifica-
tion of host-pathogen interaction components into bene-
ficial (anti-infective, host defensive) and harmful
(collateral tissue damage) subtypes could pave the way
to develop novel optimized strategies for biomarker de-
velopment and therapeutic drug targeting in CF lung
disease.
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